Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.

ABSTRACT: Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these treatment outcomes are still insufficient. Elderly MM patients are increasing, as are their treatment regimens. There is a heightened demand to assess these patients in order to provide optimized treatments. While continuous treatment is more common for MM patients when compared to fixed-duration treatment, due to the risk of treatment interruption causing reduced survival rates, effectiveness and safety are essential. Treatment goals vary for each patient, but must preserve their quality of life (QOL). When planning treatments for these patients, frailty evaluation is increasingly emphasized as a stratification factor which helps develop accurate s

SUBMITTER: Horigome Y 

PROVIDER: S-EPMC10971975 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature